breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiski līdzekļi - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
bsn finish first® n.o.- xplode™ (2017.) pulveris
bioshell teoranta - pulveris
soluro od first choice (2016.) kapsula
ražots es pēc sia "solepharm pharmaceuticals" pasūtījuma - kapsula
nannycare® first infant milk pulveris
partnerlink, sia - pulveris
nannycare® first infant milk pulveris
partnerlink, sia 40003958698 pļavnieku iela 9-22, rīga, lv-1021, latvija - pulveris - cits - mākslīgais piena maisījums zīdaiņiem
bsn finish first® nitrix® 2.0 (2017.) tablete
bioshell teoranta - tablete
nannycare® first infant milk pulveris
partnerlink, sia - pulveris
locatim (previously serinucoli)
biokema anstalt - koncentrēts liellopu laktozērs, kas satur specifiskus imūnglobulīnus g pret e. coli f5 (k99) adhezīvu - immunologicals par bovidae - teļi, jaunāki par 12 stundām - ar e saistītā enterotoksikoze izraisītās mirstības samazināšana. coli f5 (k99) adhezīvs pirmajās dzīves dienās kā papildinājums no aizsprosta jaunpiena.
whey extras pulveris (2016.) pulveris
scitec ltd - pulveris
carni+cla (2016.) kapsula
scitec kft - kapsula